AUSTIN, TX – January 19, 2009 - Specialty coatings company, AeonClad Coatings LLC, has announced the launch of a newly formed subsidiary, AeonClad Biomedical LLC. The new company will focus on biomedical applications utilizing the AeonCoat™ Technology. AeonCoat is a dry coating technology that offers a single-step, solvent-free process producing conformal films. The technology enables custom tailored coatings allowing for improved dissolution of poorly water soluble drugs, as well as modified or sustained release. Coatings can also display functional groups used for secondary covalent coupling of biological materials or for targeted drug delivery.
Key Markets and Business Development By concentrating on drug delivery and medical devices, AeonClad Biomedical is positioned to meet key market needs. The Nanotechnology-based drug delivery market is expected to garner $700-$800 billion revenues by 2015.? Expectations are that the market will be driven by the expanding horizon of therapeutic applications. Venture capital investments in nanotechnology drug delivery companies have been increasing and have provided further positive spin to the market growth.
Full article >> http://www.devicespace.com/news_story.aspx?NewsEntityId=123296
Tuesday, January 20, 2009
New Start-up AeonClad Biomedical Applies Patented Coatings Technology AeonCoat(TM) to the Drug Delivery and Medical Devices Markets
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment